Table 2 Immunohistochemistry
From: Malignancy in giant cell tumor of bone: analysis of an open-label phase 2 study of denosumab
Patient No.a (Age Range) | Histology | Immunohistochemistry | H3F3A results | |
|---|---|---|---|---|
Pre-denosumab | Post-denosumab | |||
Primary GCTB | ||||
1 (80–89 y) | Undifferentiated pleomorphic sarcoma | NA | NA | NA |
2 (50–59 y) | Undifferentiated spindle cell sarcoma | P63+, P53–, MDM2+/– (FISH not amplified) | P63–, P53−, MDM2+ (FISH not amplified) | Pre-denosumab: H3F3A– Post-denosumab: NE |
3 (20–29 y) | Osteogenic sarcoma | KI67/MIB-1 40%, focally high, PDGFR-β+, PDGFR-α– | NA | NA |
4 (70–79 y) | Undifferentiated pleomorphic sarcoma | NA | MDM2– (FISH not available), P53–, P63–, SATB2− | NE |
5 (30–39 y) | Undifferentiated pleomorphic sarcoma | MDM2+/– (FISH not available) P53–, P63− | MDM2+(FISH not available), P53+, P63– | NE |
Secondary GCTB | ||||
6 (40–49 y) | High-grade sarcoma | NA | NA | NA |
7 (40–49 y) | Undifferentiated pleomorphic sarcoma | Vimentin+, P63+, CD31–, CD34–, CKCAM5.2–, AE1–/AE3–, SMA–, S100–, and desmin– | NA | NA |
8 (40–49 y) | Undifferentiated pleomorphic sarcoma | NA | MDM2+/– (FISH not available), P53+/–, P63− | NA |
9 (20–29 y) | Giant cell tumor with suspect progression to sarcoma | MDM2+/– (FISH not available), P53+/–, P63+/–, SATB2+/– | NA | Pre-denosumab: H3F3A+ |
10 (50–59 y) | High-grade undifferentiated spindle cell sarcoma | MDM2+ (FISH not available), P53–, P63+/–, SATB2+/– In recurrences: MDM2– (FISH not available), P53–, P63–, SATB2+/– | MDM2+/– (FISH not available), P53+, P63+/–, SATB2– | Pre-denosumab: H3F3A+ (at initial diagnosis and recurrences) |
Sarcomatous transformation | ||||
11 (30–39 y) | Undifferentiated spindle cell sarcoma | P63–, P53+/–, MDM2– (FISH not available); | P63–, P53+, MDM2+ (FISH not available) | NA |
12 (60–69 y) | High-grade osteosarcoma | P63+, P53+, MDM2+ (FISH not available) | P63–, P53+, MDM2+ (FISH not available) | Pre-denosumab: H3F3A+ Post-denosumab: H3F3A+ |
13 (30–39 y) | Undifferentiated spindle cell sarcoma | P53+, MDM2+ (by FISH amplified) at malignant diagnosis but MDM2– (FISH not amplified) at initial GCTB diagnosis | NA | |
14 (50–59 y) | High-grade osteosarcoma | MDM2+/– (FISH not available), P53+/–, P63− | MDM2+ (FISH not available), P53–, P63+/–, SATB2+ | Pre-denosumab: H3F3A+ |
Misdiagnoses | ||||
15 (20–29 y) | Giant cell-rich osteosarcoma | NA | SMA+/–, S100–, Ki67/MIB1 20%CD68+, vimentin+, focally positive for CD45 and SMA, S100–, CD30–, CD15–, Ki67 showed moderately high proliferative index | NA |
16 (70–79 y) | Pleomorphic rhabdomyosarcoma | P63–, P53+, MDM2+/– (FISH not available) | P63–, P53+, MDM2+ (by FISH not amplified), desmin+, myogenin+ | Pre-denosumab: H3F3A– |
17 (40–49 y) | Undifferentiated spindle cell sarcoma | CK AE1/AE3CD68+, vimentin++, cytokeratin AE 1/3+, S100– | NA | |
18 (20–29 y) | Osteogenic sarcoma (present pre-enrollment) | NA | NA | NA |
19 (10–19 y) | Phosphaturic mesenchymal tumor of mixed connective tissue type | NA | NA | NA |
20 (30–39 y) | Undifferentiated spindle cell sarcoma | NA | NA | NA |